The Life Sciences team advised Triveni Bio Inc. on a $65 million Series C financing round to support pipeline expansion and continued corporate growth. The round was co-led by new investors Ascenta Capital and Janus Henderson Investors, with significant participation from Deep Track Capital, alongside additional existing investors. Proceeds from this financing will allow the company to extend the scope and rigor of clinical development of TRIV-573, a half-life-extended, next-generation bispecific engineered to address the underlying cause of atopic dermatitis, including an atopic dermatitis Phase 2 clinical proof-of-concept study expected to initiate later this year.
Triveni Bio is a biotechnology company at the forefront of novel antibody-based therapies for immunological and inflammatory disorders. Using a genetics-informed, precision medicine approach, the company seeks to establish proof of concept early in the drug development process by leveraging deep insights into genetic and mechanistic biology.
The Goodwin team was led by Gaby Morales-Rivera, Neil Doogan, Julia Shaver, Hayden Hunt, and Bill Collins, with invaluable assistance from Kathryn Georgian.